Our clinical analysis of SKCM and TNBC ICI cohorts revealed a correlation between increased FOXO1 expression and immunotherapy resistance, suggesting the potential immunosuppressive role of FOXO1 in tumour immunotherapy. This evidence concerns the gene FOXO1 and neoplasm.